Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
BRIEFS
December 08, 2022
Drug-resistant infections kill an estimated 33,000 EU citizens every year. Without sufficient investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from ince...
BRIEFS
December 08, 2022
Drug-resistant infections kill an estimated 5,400 Canadian citizens every year. Without sufficient R&D investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI ...
Blog Post
December 08, 2022
The world desperately needs new antibiotics—and finally, the G7 is ready match commitments with action. We already found that the US would pay $17.9 billion over 30 years but save 383,000 American lives and harvest $495 billion in value. What would be the benefits to other members of the G7, and who...
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...